Shwachman Diamond Syndrome Registry and Study (SDSR)

Shwachman Diamond Syndrome Registry and Study (SDS Registry)

Shwachman-Diamond syndrome (SDS) is a genetic condition characterized by bone marrow failure, medical co-morbidities, and leukemia predisposition. SDS-Like patients share clinical features with SDS but lack mutations in known SDS genes. Since SDS/SDS-Like syndromes are rare diseases, data are sparse regarding the clinical features, natural history, clinical outcomes with current management, and treatment. For this reason, the SDS Registry was formed to collect clinical data from medical records and to bank biological samples with the goal of understanding SDS/SDS-Like diseases to develop better treatments and improve the health of patients with these conditions.

Study Overview

• Status: Recruiting
• Conditions: Shwachman-Diamond Syndrome; Shwachman-Diamond Syndrome-Like

Detailed Description

The Shwachman-Diamond Syndrome Registry (SDSR) is dedicated to accelerating research and treatment for SDS to improve survival and quality of life for all patients with the disease. The SDSR is run jointly by Boston Children's Hospital and Cincinnati Children's Hospital Medical Center.

Objective and Aims:

The long term goals of the Registry are to improve diagnosis, inform medical management, and to develop better treatments for SDS and SDS-Like disorders.

To achieve these objectives, the Registry has the following specific aims:

• Characterize the natural history, medical complications, and treatment outcomes for patients with SDS and SDS-Like disorders.
• Investigate the molecular and genetic pathogenesis of SDS/SDS-Like conditions and their complications such as marrow failure and clonal evolution.
• Identify new genes causing SDS/SDS-Like conditions.
• Provide education on the diagnosis, medical management and treatment of SDS for patients, families and the medical/scientific community.

Methods: The SDSR collects information from medical records and biological samples. Samples for the SDSR are collected when they are obtained for clinical care so that no extra visits or procedures are needed. These samples may include blood, bone marrow, skin cells, saliva, or discards from other clinical procedures. Family members may also contribute blood samples. All information obtained by the SDSR is housed on a secure, HIPAA-compliant database. No personal information is shared outside of the study team.

• Study Type: Observational
• Enrollment (Estimated): 5000

Contacts and Locations

• Study Contact: Name: Akiko Shimamura, MD, PhD; Email: akiko.shimamura@childrens.harvard.edu
• Study Contact Backup: Name: Karyn Brundige; Email: sdsregistry-dl@childrens.harvard.edu

Study Locations

• United States
  • Colorado
    • Aurora, Colorado, United States, 80045
      • Recruiting
      • Children's Hospital Colorado
      • Contact: Taizo Nakano, MD; Email: Taizo.Nakano@childrenscolorado.org
  • Massachusetts
    • Boston, Massachusetts, United States, 02115
      • Recruiting
      • Boston Children's Hospital
      • Contact: Akiko Shimamura, MD, PhD; Email: akiko.shimamura@childrens.harvard.edu
      • Contact: Karyn Brundige; Email: sdsregistry-dl@childrens.harvard.edu
    • Boston, Massachusetts, United States, 02115
      • Recruiting
      • Dana-Farber Cancer Institute
      • Contact: Christopher R Reilly, MD; Email: ChristopherR_Reilly@dfci.harvard.edu
  • Ohio
    • Cincinnati, Ohio, United States, 45229
      • Recruiting
      • Cincinnati Children's Hospital Medical Center
      • Contact: Kasiani Myers, MD; Email: kasiani.myers@cchmc.org
      • Contact: Sara Loveless, RN; Email: sara.loveless@cchmc.org

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Child; Adult; Older Adult
• Accepts Healthy Volunteers: N/A

• Sampling Method: Probability Sample

Study Population

Patients with known or suspected SDS or SDS-Like conditions and their relatives are eligible for the study. Patients may indicate interest in participation by contacting the registry team through the website at www.sdsregistry.org.

Description

Inclusion Criteria: Shwachman Diamond syndrome, Shwachman-Diamond Syndrome-Like conditions, or a genetically undefined condition that shares clinical features with Shwachman Diamond Syndrome.

• Biallelic mutations in SBDS, or pathogenic mutations in DNAJC21, EFL1, or SRP54 OR
• Shwachman-Diamond Syndrome defined clinically OR
• Clinically suspected Shwachman-Diamond Syndrome OR
• Phenotypic features suggestive of SDS OR
• Parents, siblings, and other blood relatives of any age, living and deceased, of patients with SDS or SDS-Like conditions are eligible for this study

Exclusion Criteria:

• Patients with other diagnosed causes of bone marrow failure, exocrine pancreatic insufficiency and cancer predisposition will be excluded.

Study Plan

How is the study designed?

Number of groups / cohorts

1

Cohorts and Interventions

Group / Cohort
Patients with SDS/SDS-Like conditions and their families

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Characterize the natural history, medical complications, and treatment outcomes for patients with SDS and SDS-Like conditions.	The SDSR will collect clinical information regarding SDS and SDS-Like conditions. The goal is to understand the natural history, treatment outcomes and complications of these rare disorders in order to improve diagnosis, medical management, and treatment.	50 years
Investigate the molecular and genetic pathogenesis of SDS/SDS-Like condtions and their complications such as marrow failure and clonal evolution.	The SDSR will coordinate a repository of blood, cord blood, bone marrow, saliva, skin fibroblast, and tumor samples and cell lines from patients with SDS and SDS-Like conditions for basic science studies of molecular and genetic pathways causing these disorders and their complications. We will also study how genetic/molecular pathways may be targeted or corrected for the development of new therapies. To this end, we will create immortalized cell lines including EBV-transformed lymphoblasts, immortalized fibroblasts, and induced pluripotent stem cells. These cell lines will provide a renewable source of rare patient-derived material for these studies.	50 years
Identify new genes causing SDS/SDS-Like conditions	The SDSR will sequence DNA from patient samples to try to identify new genes that are involved in SDS/SDS-like phenotypes.	50 years
Provide education on the diagnosis, medical management, and treatment of SDS/SDS-Like conditions for patients, families, and the medical/scientific community.	The SDSR will disseminate information through the study website, conferences, and other scientific publications.	50 years

Collaborators and Investigators

• Sponsor: Boston Children's Hospital
• Collaborators: Children's Hospital Medical Center, Cincinnati

Publications and helpful links

Helpful Links

• Website for the SDS Registry

Study record dates

Study Major Dates

• Study Start (Actual): January 19, 2016
• Primary Completion (Estimated): January 1, 2090
• Study Completion (Estimated): January 1, 2090

Study Registration Dates

• First Submitted: September 14, 2023
• First Submitted That Met QC Criteria: September 25, 2023
• First Posted (Actual): September 28, 2023

Study Record Updates

• Last Update Posted (Actual): September 28, 2023
• Last Update Submitted That Met QC Criteria: September 25, 2023
• Last Verified: September 1, 2023

More Information

Terms related to this study

• Keywords: Leukemia; Pancreas; MDS; Bone marrow; Neutropenia; Cancer predisposition; Bone marrow failure; Inherited bone marrow failure syndromes
• Additional Relevant MeSH Terms: Digestive System Diseases; Pathologic Processes; Metabolic Diseases; Skin Diseases; Disease; Hematologic Diseases; Lipid Metabolism Disorders; Pancreatic Diseases; Congenital Bone Marrow Failure Syndromes; Bone Marrow Failure Disorders; Lipid Metabolism, Inborn Errors; Syndrome; Bone Marrow Diseases; Exocrine Pancreatic Insufficiency; Lipomatosis; Shwachman-Diamond Syndrome
• Other Study ID Numbers: P00020466

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No